Furthermore, the surge in chronic ailments like oncology, diabetes mellitus, cardiovascular diseases (CVD), and several infectious disorders has raised the concerns among healthcare workers and government firms alike. Governments are taking up initiatives to boost financial assistance to facilitate upgradations in the pharmaceutical sector, which is touted to benefit the drug delivery informatics market.  

Market Segmentation

To offer a comprehensive framework of the drug discovery informatics industry, MRFR has profiled product, mode, service, and end user as the key segments in the report.

The products listed in the MRFR report are development informatics and discovery informatics.

Mode-wise segments are outsourced informatics and in-house informatics.

Services considered in the report include docking, sequencing and target data analysis, clinical trial data management, molecular modeling, and more. The sequencing and target data analysis segment should lead the global market over the next couple of years, given informatics solutions’ extensive applications in targeted analysis and the massive volumes of data produced drug discovery processes.

Major industry end users are contract research organizations (CROs), pharmaceutical and biotechnology industries, and others.

Regional Status 

The drug discovery informatics industry has been geographically divided into Europe, the Americas, Asia Pacific, or APAC as well as the MEA or Middle East & Africa.

The Americas has been at the forefront of the global market for drug discovery informatics since 2017 and is deemed to remain lucrative throughout the analysis period. Strong presence of several reputed contenders like PerkinElmer Inc., Thermo Fisher Scientific, Inc., and International Business Machines Corporation ensure the region’s elite position in the global industry. Moreover, the modern healthcare infrastructure, thriving biotechnology and pharmaceutical industries, and innovations in next-generation sequencing in Canada and the US also add to the American market’s value. Majority of the vendors in the Americas indulge in research collaborations and joint ventures and this could favor the market in the following years. To illustrate, in December 2020, Atomwise Inc. reported an extensive series of joint ventures with companies like OrganAi, A2i Therapeutics and vAirus, to launch programs related to immunology, oncology, infectious disease, neuroscience and clotting disorders.

Europe is the second highest gainer in the global market and will continue thriving rapidly in the next few years, thanks to the financial aid by the government in terms of research and development activities and the surge in therapeutic discovery ventures. Rise in these activities in line with growing participation of various universities, and academic and research institutes, could further strengthen the market position in Europe.

Asia Pacific will remain a highly lucrative market from 2020 to 2027 and expand at a fast pace backed by the expanding elderly population as well as the alarming rise in chronic disorders. Soaring awareness and significant use of drug discovery informatics, combined with the mounting number of clinical trials in the region also fosters the market value. Governments across multiple countries in the region are working on encouraging the use of bioinformatics for faster medicine discovery. To cite a reference, in July 2020, the Indian government introduced Drug Discovery Hackathon; a training program aimed at discovering effective molecules to fight against COVID-19. This objective is expected to be fulfilled with the use of drug discovery informatics tools that help identify, validate, and design the lead molecule.

The MEA market for drug discovery informatics should depict a decent growth in the years ahead, especially since North Africa and the Middle East account for close to 2% of the worldwide pharmaceutical sales. Exploding population and the resultant rise in drug consumption, especially higher-yield and more effective pharmaceutical products has drawn in a number of global pharmaceutical vendors. This could be a significantly favorable factor for the MEA market in the ensuing years.

Top Contenders

The players spearheading the global market for drug discovery informatics include Jubilant Life Sciences Ltd., PerkinElmer, Inc., IO Informatics, Inc., Infosys Limited, Novo Informatics Pvt. Ltd., Dassault Systèmes, Collaborative Drug Discovery Inc., Charles River Laboratories, Inc., International Business Machines Corporation, Selvita, GVK Biosciences Private Limited, Thermo Fisher Scientific, Inc., Certara, L.P., to mention a few.

Latest News

December 2020

Curve Therapeutics Ltd. adopted the CDD Vault platform for the management of its genetically encoded Microcycle platform that can be used in numerous applications across biotechnology, academic institutes and pharmaceutical. This platform helps secure and seamlessly share data faster and in real-time, thus assisting in collaborative discoveries.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/drug-discovery-informatics-market-7831